WE’RE RAISING!! JOIN OUR SEED ROUND NOW

We’re on a mission to revolutionise the way clinicians care for patients with complex, challenging behaviours.

PROBLEM: In excess of 650 million people across the world are living with a medical condition with underlying behavioural needs - including brain injury, dementia, PTSD, learning disability and autism.

Clinical assessment of these complex patient behaviours is broken! Time consuming, manually intensive, high costs and lacking the clinical insights required for timely intervention and ongoing patient care.

SOLUTION: To tackle this problem we have built Melo™ - an award winning health tech platform which helps clinicians make better decisions through smarter, quicker behavioural assessments. Melo™ leverages cloud, data & AI to streamline clinical assessments, enhance care planning, and drive better patient outcomes.

  • Leads to >80% of clinicians reporting improved understanding of patient behaviour

  • Reduces assessment time by up to 90%

  • Increases volume of clinical datapoints by 4x

  • Reduces costs by up to 60% - less clinical resource & reduced incidents

TRACTION: With several high-impact paying customers across Private, Charitable & NHS hospitals in the UK we are now looking to grow our B2B SaaS revenue to £1m+ ARR in the next 18 months.

Longer term we aim to scale-up and diversify Melo™ with the goal of supporting 10,000,000 patients, families and clinicians over the next 10 years.

Get in touch to book a call

Our latest round

We are raising £1m - with full EIS remaining, early revenue traction, Innovate UK backing and a strong set of current VC investors.

Target close date for next round - Q2 2026.

What’s our why?

Listen to one of our co-founders talking about the inspiration behind Melo, our progress to date and plans for the future - as presented at the recent Turing Innovation Catalyst Demo Day.

Our current investors

PXN Group

PXN Group is early stage VC of choice for founders & investors. With backing from the GM Life Sciences fund for early stage health tech.

innovate UK

Innovate UK have backed us with numerous grants including a new £360k Investor Partnership fund.

SFC Capital

SFC is a leader in the UK's early stage investment world, providing seed capital and support to promising British start-ups.

Angel investors

We have been lucky enough to secure the early backing and mentorship of some fantastic Angel investors and syndicate groups.

REGISTER INTEREST FOR OUR SEED ROUND INVESTMENT DECK

  • Great to hear you are interested. Why not drop us a line to register your interest in receiving our full investment pitch deck, or if you are ready for an initial chat then we would love to hear from you. Why not send us an email here?

  • Yes, we received SEIS/EIS advanced assurance approval from HMRC in January 2022. However, we have now utilised our full SEIS allowance but can still offer full EIS relief for another 4 years - helping you to minimise your risk.

    Further info about how SEIS/EIS works for you as an investor can be found here.

  • We would be more than happy to share our full 5 year financial plan with you as part of your due diligence. If you are ready to start the conversation then get in touch with us here.

  • Our product site for Melo provides an overview of the problem we are looking to solve together with an insight into the app itself, our compliance credentials and partners we are working with. There is also a downloadable one page overview which you might find of interest.

    We would be more than happy to give you a closer look at the product, setup time with our CTO or go into any of the technical detail as part of your due diligence.

  • This webpage and its contents (“this prospectus”) are confidential to Decently Limited and the intended recipient(s) and may contain confidential information. This prospectus has been delivered to interested parties for information only and on the express understanding that they shall use it only for informing potential investment interest. If you are not the intended recipient of this prospectus, you must take no action based upon it, nor must you copy it or show it to anyone. Please contact Decently if you believe you have received this prospectus in error.

    The information in this prospectus, which does not purport to be comprehensive, has been provided by Decently Limited and has not been independently verified. While the prospectus has been prepared in good faith, no representation, warranty, assurance or undertaking (express or implied) is or will be made, and no responsibility or liability is or will be accepted by Decently Limited or by its officers, employees or agents in relation to the adequacy, accuracy, completeness or fairness of the information and opinions in this prospectus, or of any other information (whether written or oral), notice or document supplied or otherwise made available to any interested party or its advisers in connection with informing potential investment interest. All and any such responsibility and liability is expressly disclaimed to the extent permitted by law.

    In particular, but without prejudice to the generality of the foregoing, no representation, warranty, assurance or undertaking is given as to the achievement or reasonableness of any future projections, management estimates, prospects or returns contained in this prospectus, or in such other information, notice or document; these forward-looking statements should not be relied upon as an accurate prediction of future performance. The recipient of this prospectus acknowledges and agrees that no person has, nor is held out as having, any authority to give any statement, warranty, representation, assurance or undertaking on behalf of Decently Limited in connection with informing potential investment interest.